EVNIN LUKE 4

What Happened
Luke Evnin, a director of Werewolf Therapeutics, sold 157,084 shares of HOWL on June 29, 2026. The reported weighted-average price was $0.30 per share for total proceeds of about $47,125. The shares were sold in multiple transactions at prices ranging from $0.2703 to $0.33.

Key Details

• Date of transaction: 2026-06-29. Weighted-average price: $0.30; price range: $0.2703–$0.33.
• Total shares sold: 157,084; total proceeds ≈ $47,125.
• Breakdown of shares sold by entity (per filing): 16,830 by MPM Asset Management LLC; 106,262 by MPM BioVentures 2014, L.P.; 7,087 by MPM BioVentures 2014(B), L.P.; 3,657 by MPM Asset Management Investors BV2014 LLC; 23,248 by MPM Oncology Innovations Fund, L.P.
• Shares held after the sales (per filing): 15,341 (AM LLC); 96,873 (BV 2014); 6,459 (BV 2014(B)); 3,332 (AM BV2014); 21,194 (MPM OIF).
• Sale executed pursuant to a Rule 10b5-1 trading plan dated March 26, 2026. The filer disclaims beneficial ownership except to the extent of his pecuniary interest in the funds/entities involved.
• Filing date and Period of Report: 2026-06-29. No late filing is indicated in the report.

Context
These sales were of shares held by investment vehicles and were made under a pre-established 10b5-1 plan, which is a common mechanism for scheduled insider sales. Sales do not necessarily indicate the insider’s view of the company’s prospects; purchases are generally more informative about insider sentiment.